Preview

Атеротромбоз

Расширенный поиск

ВАРФАРИН: МЕСТО В СОВРЕМЕННОЙ АНТИКОАГУЛЯНТНОЙ ТЕРАПИИ

https://doi.org/10.21518/2307-1109-2016-1-50-58

Полный текст:

Аннотация

Фибрилляция предсердий является наиболее частым кардиальным источником системной эмболии и кардиоэмболического инсульта. Антикоагулянты рекомендованы для предотвращения инсульта у больных с неклапанной фибрилляцией предсердий. Варфарин уменьшает риск инсульта у пациентов с фибрилляцией предсердий приблизительно на две трети. В течение последних лет все большее распространение получают новые пероральные антикоагулянты. Но, несмотря на это, остается ряд клинических ситуаций, когда единственно возможным антикоагулянтом является варфарин. 

Об авторах

Н. А. Новикова
Первый Московский государственный медицинский университет им. И.М. Сеченова, Москва
Россия
Доктор медицинских наук, профессор


А. Н. Воловченко
I.M. Sechenov First Moscow State Medical University
Россия


Список литературы

1. Camm AJ, Lip GY, De Caterina R, Savelieva I et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. European Heart Journal, 2012, 33: 2719-2747.

2. Skanes AC, Healey JS, Cairns JA et al; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol, 2012 Mar-Apr, 28(2): 125-36.

3. January CT, Wann ST, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society: Executive summary. JACC, 2014: DOI:10.1016/j.jacc.2014.03.021.

4. Сулимов В.А. и коллектив авторов. Национальные рекомендации по диагностике и лечению фибрилляции предсердий, 2012.

5. Camm AJ, Lip GY, De Caterina R, Savelieva I et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. European Heart Journal, 2012, 33: 2719-2747.

6. Eikelboom JW, Connolly SJ, Brueckmann M et al. Dabigatran versus warfarin in patients with mechanical heart valves. The New England Journal of Medicine, 2013, 369(13): 1206-1214.

7. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for CardioThoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J, 2012, 33: 2451-2496.

8. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM, ROCKET AF Steering Committee & Investigators. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J, 2014, 35: 3377-3385.

9. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH. Apixaban compared with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the ARISTOTLE trial. Circulation, 2015, 132: 624-632.

10. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes, 2008, 1: 84-91.

11. Gallego P, Roldan V, Marin F, Romera M, Valdes M, Vicente V, Lip GY. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost, 2013, 110: 1189-1198.

12. Sjogren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Sjalander A. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost, 2015, 113: 1370-1377.

13. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis — Task Force on Anticoagulants in Heart Disease. Thromb Haemost, 2013, 110: 1087-1107.

14. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, 2014, 383: 955-962.

15. Gallego P, Roldan V, Marin F, Galvez J, Valdes M, Vicente V, Lip GY. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med, 2014, 127: 1083-1088.

16. Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMeTT(2)R(2) score to poorquality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest, 2014, 146: 719-726.

17. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest, 2013, 144: 15551563.

18. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 2013, 381: 1107-15.

19. Fiedler KA, Maeng M, Mehilli J et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol, 2015, 65: 1619-1629.

20. Paikin JS, Wright DS, Crowther MA, Mehta SR, Eikelboom JW. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation, 2010, 121: 2067-2070.

21. Lip GY, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary — Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J, 2010, 31: 13111318.

22. Faxon DP, Eikelboom JW, Berger PB et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv, 2011, 4: 522-534.

23. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D, Document R, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, Zamorano JL. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J, 2014, 35: 3155-3179.

24. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol, 2007, 64(3): 292-303.

25. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug metab dispos: biol fate chem., 2009, 37(1): 74-81.

26. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos, 2009, 37(5): 1056-1064.

27. Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol, 2012, 52(1 Suppl): 119S-125S.

28. Lehr T, Haertter S, Liesenfeld KH, Staab A, Clemens A, Reilly PA, Friedman J. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol., 2012, 52(9): 1373-1378.

29. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation, 2014, 130(23): 2071-104.

30. Bauer KA. Pros and cons of new oral anticoagulants. Hematol Am Soc Hematol Educ Program. 2013, 2013: 464-70.

31. Dugi K. US FDA Grants Breakthrough Therapy Designation to Pradaxa (dabigatran etexilate) specific Investigational Antidote [Boehringer-Ingelheim press release]. Ingelheim, Germany, 2014.

32. Portola-Pharmaceuticals. Andexanet alpha: FXa inhibitor antidote: Portola Pharmaceuticals, 2014.

33. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J, 2013, 34(27): 2094-106.

34. Albert NM. Use of novel anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. Heart Lung, 2014, 43: 48-59.

35. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, 17: 1467-1507.


Для цитирования:


Новикова Н.А., Воловченко А.Н. ВАРФАРИН: МЕСТО В СОВРЕМЕННОЙ АНТИКОАГУЛЯНТНОЙ ТЕРАПИИ. Атеротромбоз. 2016;(1):50-58. https://doi.org/10.21518/2307-1109-2016-1-50-58

For citation:


Novikova N.A., Volovchenko A.N. WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAY. Atherothrombosis Journal. 2016;(1):50-58. (In Russ.) https://doi.org/10.21518/2307-1109-2016-1-50-58

Просмотров: 502


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)